Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Rafael Holdings, Inc. (RFL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: RFL (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $0
1 Year Target Price $0
| 0 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -48.02% | Avg. Invested days 23 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 58.27M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.92 | 52 Weeks Range 1.27 - 3.19 | Updated Date 06/29/2025 |
52 Weeks Range 1.27 - 3.19 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.92 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1633.43% |
Management Effectiveness
Return on Assets (TTM) -9.82% | Return on Equity (TTM) -26.78% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 21022811 | Price to Sales(TTM) 79.6 |
Enterprise Value 21022811 | Price to Sales(TTM) 79.6 | ||
Enterprise Value to Revenue 28.72 | Enterprise Value to EBITDA 5.39 | Shares Outstanding 34303200 | Shares Floating 15495922 |
Shares Outstanding 34303200 | Shares Floating 15495922 | ||
Percent Insiders 54.74 | Percent Institutions 9.37 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Rafael Holdings, Inc.
Company Overview
History and Background
Rafael Holdings, Inc. is a holding company that focuses on developing and commercializing pharmaceutical products and investing in real estate assets. It has evolved through strategic acquisitions and investments, initially with a focus on real estate and more recently pivoting towards oncology therapeutics.
Core Business Areas
- Pharmaceutical Development: Focuses on the development and commercialization of novel oncology therapeutics. This includes research and clinical trials.
- Real Estate: Invests in and manages commercial real estate properties.
Leadership and Structure
The company is led by its CEO and executive team, with a board of directors overseeing strategic direction. The organizational structure includes dedicated teams for pharmaceutical research and development, clinical trials, and real estate management.
Top Products and Market Share
Key Offerings
- CPI-613 (devimistat): Devimistat is a mitochondrial metabolism inhibitor being developed as a potential treatment for various cancers, including pancreatic cancer and acute myeloid leukemia (AML). While market share data is not publicly available due to the drug being in clinical trials, the market for pancreatic cancer and AML treatments is substantial, with competitors like Eli Lilly (Gemzar) and Novartis (Rydapt).
- Real Estate Portfolio: A portfolio of commercial real estate properties. Revenue from this portfolio contributes to the company's overall financial performance. Market share data for the real estate holdings is not specific due to the diverse geographic locations and types of properties.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive, with companies vying to develop and commercialize new therapies. The real estate market is influenced by economic conditions, interest rates, and demographic trends.
Positioning
Rafael Holdings is positioned as a biotech company focused on targeted therapies for unmet medical needs, particularly in oncology. Their competitive advantage lies in their novel approach to cancer treatment through mitochondrial metabolism inhibition and diversified income through real estate.
Total Addressable Market (TAM)
The TAM for oncology therapeutics is estimated to be over $200 billion globally. Rafael Holdings, with its Devimistat program targeting aggressive cancers such as pancreatic cancer, is positioned to capture a segment of this substantial market. The real estate portion of TAM is dependent on region. It is difficult to measure the real estate TAM accurately.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach (mitochondrial metabolism inhibition)
- Experienced management team
- Diversified revenue streams (pharmaceutical and real estate)
- Potential for breakthrough cancer treatments
Weaknesses
- Limited revenue from pharmaceutical products (currently in development)
- Dependence on clinical trial outcomes
- Competition from larger pharmaceutical companies
- Significant cash burn due to R&D expenses
Opportunities
- Successful clinical trial results and FDA approval
- Strategic partnerships and collaborations
- Expansion of real estate portfolio
- Potential for orphan drug designation and accelerated approval pathways
Threats
- Clinical trial failures
- Regulatory hurdles and delays
- Competition from established cancer therapies
- Economic downturn impacting real estate values
- Changes in healthcare reimbursement policies
Competitors and Market Share
Key Competitors
- Eli Lilly (LLY)
- Novartis (NVS)
- Bristol Myers Squibb (BMY)
Competitive Landscape
Rafael Holdings faces significant competition from larger, more established pharmaceutical companies with greater resources. Its competitive advantage lies in its novel therapeutic approach, but it must successfully navigate clinical trials and regulatory hurdles to gain market share.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been primarily driven by real estate investments and, more recently, pharmaceutical development efforts.
Future Projections: Future growth is heavily dependent on the successful development and commercialization of Devimistat and other pipeline products. Analyst estimates vary, but the potential for significant revenue growth exists if clinical trials are successful.
Recent Initiatives: Recent strategic initiatives include advancing Devimistat through clinical trials, seeking partnerships with pharmaceutical companies, and optimizing the real estate portfolio.
Summary
Rafael Holdings is a company at a pivotal point. Its future hinges on the success of its pharmaceutical development, particularly Devimistat. While the real estate holdings provide a stable revenue stream, the company needs successful clinical trials to drive significant growth. The company faces significant risks in a highly competitive market and must navigate regulatory hurdles effectively to realize its potential. With the minimal information available to the public, the company seems weak due to the significant cash burn from R&D expenses and lack of drug sales.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share data is approximate and may vary depending on the source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Rafael Holdings, Inc.
Exchange NYSE | Headquaters Newark, NJ, United States | ||
IPO Launch date 2018-03-26 | CEO, Founder & Executive Chairman Mr. Howard S. Jonas | ||
Sector Real Estate | Industry Real Estate Services | Full time employees 28 | Website https://www.rafaelholdings.com |
Full time employees 28 | Website https://www.rafaelholdings.com | ||
Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), a stable analog of transient, acylated catalytic intermediates of lipoate currently under phase 2 open-label multi-cohort study evaluating CPI-613 in combination with hydroxychloroquine and 5-fluorouracil or gemcitabine in patients with advanced chemorefractory colorectal, pancreatic, or other solid cancers; and under phase 1 dose-escalation study of CPI-613 in combination with chemoradiation in patients with pancreatic adenocarcinoma. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1A and 1B clinical studies targeting patients with advanced cancers; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrument for Carpal Tunnel syndrome. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.